LLY

981.29

-2.24%↓

JNJ

239.53

-2.3%↓

ABBV

232.07

-1.66%↓

NVS

160.95

-2.49%↓

AZN

197.36

-2.11%↓

LLY

981.29

-2.24%↓

JNJ

239.53

-2.3%↓

ABBV

232.07

-1.66%↓

NVS

160.95

-2.49%↓

AZN

197.36

-2.11%↓

LLY

981.29

-2.24%↓

JNJ

239.53

-2.3%↓

ABBV

232.07

-1.66%↓

NVS

160.95

-2.49%↓

AZN

197.36

-2.11%↓

LLY

981.29

-2.24%↓

JNJ

239.53

-2.3%↓

ABBV

232.07

-1.66%↓

NVS

160.95

-2.49%↓

AZN

197.36

-2.11%↓

LLY

981.29

-2.24%↓

JNJ

239.53

-2.3%↓

ABBV

232.07

-1.66%↓

NVS

160.95

-2.49%↓

AZN

197.36

-2.11%↓

Home・Akciju saraksts・Myriad Genetics Inc

Myriad Genetics Inc

Slēgts

SektorsVeselības aprūpe

5.12 -3.03

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

4.97

Max

5.32

Galvenie mērījumi
By Trading Economics
Ienākumi	303M -27M
Pārdošana	4.1M 210M
Peļņas marža	-13.32
Darbinieki	2,700
EBITDA	-50M -60M

Rekomendācijas
By TipRanks
Rekomendācijas	Neitrāls
Prognoze 12 mēnešiem	+24.39% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 5. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	48M 467M
Iepriekšējā atvēršanas cena	8.15
Iepriekšējā slēgšanas cena	5.12

Ziņu noskaņojums

By Acuity

50%

168 / 351 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bearish Evidence

N/A / 7.55 Atbalsts un pretestība

Myriad Genetics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 5. marts 23:01 UTC

Peļņas

Costco Evaluating Possibility of Tariff Refunds as 2Q Revenue Rises - Update

2026. g. 5. marts 21:54 UTC

Peļņas

Costco Posts Higher 2Q Profit on Rising Sales, Membership Fees

2026. g. 5. marts 21:35 UTC

Galvenie tirgus virzītāji

ServiceNow Shares Rise After CEO Says AI Can Add Value to Software

2026. g. 6. marts 00:00 UTC

Galvenie ziņu notikumi

Its Missile Threat Degraded, Iran Is Taking Fewer Shots at More Targets -- WSJ

2026. g. 5. marts 23:46 UTC

Tirgus saruna

Nikkei May Decline Amid Concerns About Energy Costs -- Market Talk

2026. g. 5. marts 23:33 UTC

Tirgus saruna

Gold Edges Higher on Possible Technical Recovery -- Market Talk

2026. g. 5. marts 23:27 UTC

Tirgus saruna

Middle East Fighting Will Prompt RBA to Delay Hike -- Market Talk

2026. g. 5. marts 22:54 UTC

Tirgus saruna

Peļņas

Costco Sold a $150,000 Diamond Ring in 2Q -- Market Talk

2026. g. 5. marts 22:50 UTC

Tirgus saruna

Woodside Has More Exposure to Rising Gas Prices Than Santos -- Market Talk

2026. g. 5. marts 22:48 UTC

Peļņas

Nike Reports $300 Million Pretax Charge Related to Job Cuts -- Barrons.com

2026. g. 5. marts 22:46 UTC

Peļņas

Costco Evaluating Possibility of Tariff Refunds as 2Q Revenue Rises -- Update

2026. g. 5. marts 22:44 UTC

Peļņas

Costco Earnings Beat Expectations as Membership Model Shines -- Barrons.com

2026. g. 5. marts 21:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 5. marts 21:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 5. marts 21:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 5. marts 21:35 UTC

Peļņas

Marvell Earnings Beat Estimates on 'Robust' AI Demand. The Stock Jumps. -- Barrons.com

2026. g. 5. marts 21:32 UTC

Peļņas

Costco Earnings Beat Expectations as Membership Model Shines -- Barrons.com

2026. g. 5. marts 21:26 UTC

Peļņas

These Stocks Are Today's Movers: Broadcom, Trade Desk, Berkshire Hathaway, Rigetti, Corning, Ciena, Expedia, and More -- Barrons.com

2026. g. 5. marts 21:24 UTC

Peļņas

Costco February Digitally-Enabled Sales Ex-Changes in Gas and Foreign Exchange Rose 20.8% >COST

2026. g. 5. marts 21:23 UTC

Peļņas

Costco February Same-Store Sales Ex-Changes in Gas and Foreign Exchange Rose 7% >COST

2026. g. 5. marts 21:22 UTC

Peļņas

Costco 2Q Same-Store Sales Ex-Changes in Gas and Foreign Rose 6.7% >COST

2026. g. 5. marts 21:21 UTC

Peļņas

Costco February Digitally-Enabled Sales Rose 21.8% >COST

2026. g. 5. marts 21:21 UTC

Peļņas

Costco Total Co Comparable Sales for February Rose 7.9% >COST

2026. g. 5. marts 21:20 UTC

Peļņas

Costco February Net Sales Were $21.69 B >COST

2026. g. 5. marts 21:20 UTC

Peļņas

Marvell Earnings Beat Estimates on 'Robust' AI Demand. The Stock Jumps. -- Barrons.com

2026. g. 5. marts 21:20 UTC

Peļņas

Costco Same-Store Sales Ex-Changes in Gas and Foreign Rose 6.7% >COST

2026. g. 5. marts 21:19 UTC

Peļņas

Costco 2Q Digitally-Enabled Sales Ex-Changes in Gas and Foreign Exchange Rose 21.7% >COST

2026. g. 5. marts 21:18 UTC

Peļņas

Costco 2Q Digitally-Enabled Sales Rose 22.6% >COST

2026. g. 5. marts 21:18 UTC

Peļņas

Costco 2Q Same-Store Sales Up 7.4% >COST

2026. g. 5. marts 21:15 UTC

Peļņas

Costco 2Q EPS $4.58 >COST

Salīdzinājums

Cenas izmaiņa

Myriad Genetics Inc Prognoze

Cenas mērķis

By TipRanks

24.39% augšup

Prognoze 12 mēnešiem

Vidējais 6.58 USD 24.39%

Augstākais 8.5 USD

Zemākais 4 USD

Pamatojoties uz 8 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Myriad Genetics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

8 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 8 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Myriad Genetics Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

N/A / 7.55Atbalsts un pretestība

Recent bearish events outweigh bullish events.

There is one bearish event.

All events are bearish.

Noskaņojums

By Acuity

168 / 351 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Myriad Genetics Inc

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. It offers molecular diagnostic tests for oncology, and women's and pharmacogenomics. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status with ovarian cancer. It offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, Onsite Women's Health, and Flatiron Health, Inc.; and collaboration to study the use of MRD testing in breast cancer. The company was incorporated in 1992 and is headquartered in Salt Lake City, Utah.